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Novelty and Impact
At our knowledge this is the first time that a higher risk of second primary cancers after a breast
cancer is described using cohort data,  with a rich database on breast  cancer risk factors.  These
findings are useful for health services planning, including screening and the development of specific
guidelines for the follow-up of breast cancer patients.
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Abstract
Women with a diagnosis of breast cancer are at increased risk of second primary cancers, and the
identification of risk factors for the latter may have clinical implications.
We have followed-up for 11 years 10,045 women with invasive breast cancer from a European
cohort,  and  identified  492  second  primary  cancers,  including  140  contralateral  breast  cancers.
Expected and observed cases and Standardized Incidence Ratios (SIR) were estimated  using Aalen-
Johansen Markovian methods.
Information on various risk factors was obtained from detailed questionnaires and anthropometric
measurements. Cox proportional hazards regression models were used to estimate the role of risk
factors.
Women with breast cancer had a 30% excess risk for second malignancies (95% confidence interval
-  CI  -  18-42)  after  excluding  contralateral  breast  cancers.  Risk  was  particularly  elevated  for
colorectal  cancer  (SIR,  1.71,  95%  CI  1.43-2.00),  lymphoma  (SIR  1.80,  95%  CI  1.31-2.40),
melanoma (2.12; 1.63-2.70), endometrium (2.18; 1.75-2.70) and kidney cancers (2.40; 1.57-3.52).
Risk of second malignancies was positively associated with age at first cancer, body mass index and
smoking  status,  while  it  was  inversely  associated  with  education,  post-menopausal  status  and a
history of  full-term pregnancy.
We describe in a  large cohort  of women with breast  cancer  a 30% excess of second primaries.
Among risk factors for breast cancer, a history of full-term pregnancy was inversely associated with
the risk of second primary cancer.
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Introduction
Multiple primary malignancies are independent cancers (i.e. not metastases) that arise subsequently
to  a  first  malignancy,  at  the  same  site  or  in  different  parts  of  the  body.  During  last  decades,
improvements  in  medical  and  surgical  treatments  have  substantially  increased  the  chances  of
surviving from a cancer. Cancer survivors now represent more than 3.5% of the population in the
US1, and about 3% in Western Europe2. Cancer survivors face the problem of subsequent primary
tumours,  possibly related to the late  effects  of treatment  or to a common aetiology for multiple
cancers.
Previous investigations suggested that cancer patients have a 15-20% higher risk of a second primary
cancer compared with the general population. Approximately one third of cancer survivors aged >60
years are diagnosed at least once with a second cancer3. Women with breast cancer as first primary
were the largest group of multiple cancer patients in the United States in 2002, while the second and
third groups were men and women with a diagnosis  of primary colorectal  cancer  and men with
prostate cancer, respectively4. Descriptive data on multiple primary cancers4-9 suggest that there is a
generalised excess for several tumour types among cancer survivors. 
There is a growing interest in identifying possible causes of multiple malignancies and research has
focused so far on host factors, such as hormonal and/or genetic factors10, lifestyle and environment,
or treatment of the first cancer14. In particular, it  is well established that radiotherapy can induce
acute  myeloid  leukaemia  (during  the  first  two  years  after  treatment15)  and  breast  and  thyroid
cancers16. Acute myeloid leukemia is a late effect of adjuvant chemotherapy for breast cancer, as a
consequence of prior exposure to alkylating agents and to topoisomerase II inhibitors17. Moreover, an
increased risk of endometrial cancer was associated with a late effect of Tamoxifen therapy. Two
recent papers from cancer registries in the United States20  and in England21 analysed the role of
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radiotherapy on the risk of developing a second tumour. Both studies estimated that about 8% of
second tumours are due to radiotherapy.
The aims of our study were to assess the incidence of second primary malignancies in a large
prospective  European  cohort  of  breast  cancer  patients,  and  to  identify  risk  factors  for  second
primary cancers. We report on a population-based study of 10,045 women with newly diagnosed
breast cancer, with a rich database on breast cancer risk factors that were not available in previous
investigations. 
Subjects and methods
The EPIC cohort
The European Prospective Investigation into Cancer and Nutrition (EPIC) study was designed as a
prospective study to investigate the relationship between diet, lifestyle, genetic and environmental
factors and the incidence of cancer  and other chronic diseases.  The study has been extensively
described elsewhere. Briefly, more than 500,000 healthy subjects aged 35-70 years (~70% women)
were recruited from 1992 to 1998 in 23 centres from 10 European countries: Denmark, France,
Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom. Most of
the  subjects  were  recruited  from  the  general  population,  except  the  French  cohort  (based  on
members of a national health insurance plan mostly covering teachers), the Utrecht and the Florence
cohorts (based on women attending breast cancer screening programmes), part of the other Italian
and Spanish cohorts (based on blood donors) and the Oxford cohort (based mostly on vegetarians).
All participants signed an informed consent form. Approval for this study was obtained from the
ethical  review  boards  of  the  International  Agency  for  Research  on  Cancer  and  of  all  local
participating centres.
Lifestyle and dietary questionnaires
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All  subjects  completed  two questionnaires  and about  80% of them donated a blood sample.  A
lifestyle  questionnaire  was  used  to  investigate  reproductive  histories  (including  the  number  of
pregnancies) , use of hormones (including HRT), education, physical activity,  lifetime history of
smoking and alcohol intake, occupation, history of major diseases (such as cancer, hypertension,
diabetes) and history of surgical operations. A dietary questionnaire was used to investigate the
previous year's diet and was based on 88 to 266 centre-specific food items24. 
Follow-up and identification of second cancers
The follow-up was based on population cancer registries, except in France, Germany and Greece,
where  a  combination  of  methods,  including  health  insurance  records,  cancer  and  pathology
registries and active follow-up were used.  
Incident cancers (eg. primary cancers occurring after the subject’s recruitment in the EPIC Study)
were coded using the International  Classification of Diseases for Oncology,  3 rd revision.  Breast
cancers included all cancers with invasive behaviour, “C50” as topography and all morphologies
that were not from 9800 to 9949 (leukaemias) and not 959*, from 9650 to 9673, 976*, 982*, 983*
and 985* (lymphomas).
After exclusion of prevalent cancer cases (all but non-melanoma skin cancer), in order to identify
only women with breast cancer as their first cancer, and cases identified using death certificate only,
each primary malignancy in a single patient was recorded as a separate entry. The IARC and IACR
rules25 have been used to establish whether the newly detected tumour in the same patient was a
new primary tumour, an extension or a recurrence of an existing cancer. In particular, only one
tumour in an organ or pair of organs or tissue was included (with the exception of systemic or
multicentre cancer, potentially involving many discrete organs, and some specific histologies that
are considered to be different for the purpose of defining multiple tumours; e.g. adenocarcinomas
and  sarcomas  in  the  same  organ  are  considered  as  two  primaries).  Following  these  rules,
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contralateral  breast  cancer  should not be registered as a second primary,  unless it  belongs to a
different histology type.  However, contralateral  breast cancer was registered within some of the
EPIC  cohorts  (France,  United  Kingdom,  the  Netherlands,  Sweden,  Denmark  and  Norway);
therefore, we have estimated separately the incidence of second breast cancers in these areas. We
excluded from our analysis non-melanoma skin cancers and synchronous tumours (i.e. same date of
incidence).
Statistical analyses
Estimation of incidence rates and ratios
To  correctly  assess  the  incidence  of  second  primary  tumours,  we  applied  a  Markov  model
estimating  the  transition  intensities  from first  to  second  tumour  with  the  Aalen-Johansen  (AJ)
estimators26,  as  usually  done  in  competing  risk  models.8 The  model  satisfies  the  Markov
assumption,  since it  does not take into consideration  past transitions  from healthy state  to  first
tumour.  The  Markov  model  was  applied  to  the  cohort  with  two  different  irreversible  and
reciprocally  exclusive  outcomes:  death  and  second  tumour  occurrence.  To  estimate  expected
numbers, occurrence probabilities - conditioned on the occurrence of a second cancer or death -
were  computed  in  each  time  interval  with  the  Aalen-Johansen  method,  in  the  framework  of  a
Markov process. 
Standardized  Incidence  Ratios  (SIR)  were  used  to  compare  expected  (following  general  EPIC
cohort rates) and observed numbers of  second primary cancers27. Analyses of contralateral breast
cancers were limited to centres that registered them. 
Risk factors analysis
The differences between the women with breast cancer only and those with a second primary were
tested using chi-square tests or t-tests, for qualitative and quantitative variables, respectively. Crude
semi-parametric Cox proportional hazards regression models were computed to investigate the role
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of baseline risk factors (age, BMI, smoking status, alcohol, hormone use, education, menopausal
status, pregnancy, number of children, nutrients) in the development of a second tumour after breast
cancer. In the Cox model, women started accruing person time after the diagnosis of first tumour
and were censored at  death or at  second tumour  diagnosis  or at  the end of follow-up. A fully
adjusted model was also performed to take into account possible confounding factors. Analyses
were performed for all second tumours, for all second tumours except breast cancer, and for each
group of second tumours (women with a self-declared hysterectomy at the baseline were excluded
from the  corpus-uteri  analyses).  Subjects  with  missing  values  for  some of  the  variables  in  the
models were excluded from the analysis.  An analysis by stage (PT1 – Primary Tumour stage 1 – vs
PT2 and PT1 vs PT3 or more) was performed in the sub-sample for which these data are available.
All analyses were performed using SAS v 9.2 (SAS Institute Inc., Cary, NC, USA) and STATA/IC
10.1 (StataCorp LD, College Station, TX, USA).
Results
A total of 368,010 women were recruited in the EPIC studies and 19,953 were excluded form this
study because of a prevalent tumour. Incident rates are consistent with the general population. 
Table 1 shows the general characteristics of the cohort of 10,045 women who developed breast
cancer over the 11 years of follow-up in the EPIC cohort. Women with breast cancer only differed
from those who developed second primary cancers with regard to smoking status, educational level,
menopausal  status,  history of full  term pregnancy and TNM status,  with statistically significant
differences in univariate analyses. We found no statistically significant differences concerning age
(mean age in both cohorts: 60), BMI (borderline significant with an excess of overweight and obese
women in the cohort with second primary malignancies), history of breast feeding, and intake of
major nutrients . 
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Table  2  shows  the  age-standardized  incidence  rates  of  second  primaries  by  country  and  broad
European areas. Rates are overall higher in Northern Europe. Rates in Greece and Spain are unstable
due to small numbers. Standardized Incidence Ratios by site of second primary cancer, and their 95%
confidence intervals are shown in Table 3. Overall, there is a 30% excess of second primary cancers
if we exclude breast cancers as second malignancy; if we include them, the excess is 18%, but it is
estimated in a limited number of countries only. The excess was more apparent for colorectal cancer
(SIR  1.71,  95%  CI  1.43-2.0),  melanoma  (2.12;  1.63-2.70),  endometrium  (2.18;  1.75-2.70),
lymphoma (1.80; 1.31-2.40) and kidney cancers (2.40; 1.57-3.52). When we grouped together second
cancers potentially attributable to local radiotherapy for breast cancer (oesophagus, stomach, lung,
thyroid), the excess was 33%, very similar to the overall excess. 
When we considered the association of second primaries with risk factors for breast cancer (Table 4),
risk of second primary malignancies was positively associated with age at first cancer, BMI, and
smoking  status,  while  an  inverse  association  was  found  with  educational  level,  postmenopausal
status, and history of full-term pregnancy. The change of the effect of postmenopausal status from
univariate  to  multivariate  model  is  mainly  due,  as  expected,  to  the  age-adjustment.  We  also
considered alcohol intake, use of hormone replacement therapy and the number of pregnancies, but
none of these variables showed an association with risk (data not shown). Age at first tumor was a
risk factor  for all  the sub-sites  analyzed (Supplementary Table  1 to 5),  while education  resulted
negatively associated with the risk of second colon cancer only. Full term pregnancy seemed to be
inversely associated with a risk of second breast and colon cancers; no effects were shown for full
term pregnancy when analyses were performed excluding breast, corpus uteri, and ovarian cancer
(HR: 0.73; 0.53-1.02, p-value: 0.07). Post-menopausal status resulted to be inversely associated with
a risk of second colon cancer and seemed to be a risk factor for second corpus uteri cancer. An
inverse association of total dietary fiber intake was found for second breast cancer and an increased
risk for smokers was found, as expected, for second lung cancer.
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Women with a higher stage first breast cancer (pT3 or more) were significantly at higher risk to
develop any other second cancer, except breast cancer (HR: 10.99, 95% CI 7.12-16.96 for all cancer
except breast; HR: 47.03, 95% CI 16.63-133.02 for colon cancer) (Table 5).
Discussion
In the present prospective study we observed an overall 30% excess of second primary cancers after
a breast cancer diagnosis.  Risk of second malignancies was positively associated with age  at first
cancer, body mass index and smoking status, while it was inversely associated with education, post-
menopausal status and a history of full-term pregnancy (even if this last association disappears after
exclusion of second breast, corpus uteri, and ovarian cancer).
Data from the Surveillance Epidemiology and End Results (SEER), based on 320,000 US primary
breast  cancer  patients  diagnosed  after  1973,  showed  an  excess  risk  for  developing  a  second
malignancy,  including  contralateral  breast  cancer  (observed-to-expected  ratio  of  1.18),  with  the
excess risk concentrated in patients with earlier  ages at  first  cancer diagnosis (<40, observed-to-
expected ratio 3.33) [4]. In a study from the Netherlands on 9,900 women with primary breast cancer
the standardized rate ratio for the second primaries, including contralateral breast cancer, was 2.4
(95%  confidence  interval  2.3-2.5)9.  Other  smaller  studies  found  excesses  for  all  malignancies
(generally with rate ratios in the order of 1.15-1.2), or for selected malignancies5. In a recent paper
based on Spanish data7 the authors describe a significant overall increase in the incidence of second
primary cancers in the last 30 years (p-value for trend=0.007). Our result is in line with most papers.
When considering specific cancer sites, in most cases our findings were consistent with previous
observations, including for endometrium, colorectum, oesophagus, lung, thyroid and melanoma. We
found a substantial  increase in risk of developing a second primary kidney cancer  after  a breast
cancer. This finding is novel, as kidney cancer was not observed to occur more frequently after a first
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primary breast cancer diagnosis in any of the previously cited studies. In addition, we did not observe
an excess for ovarian cancer, sarcomas, bone cancers and leukaemias unlike other investigations.
Also, the excess in risk that we observed for contralateral breast cancer, in the areas where this was
investigated,  was lower than found elsewhere.  These discrepancies could be in part  attributed to
variability in case completeness across centres, even if most of the areas in which our study was
conducted are covered by cancer registries with a coverage that is supposed to be close to 100%
according to IARC's Cancer in Five Continents programme25. A possible explanation could be the
higher socio-economic status of the EPIC participants compared to the general population observed
in  population-based  studies.  Another  alternative  explanation  for  the  higher  incidence  of  second
primary tumours  observed in our study could be a more intensive screening approach in women
diagnosed with breast cancer; however, this hypothesis is not supported by the apparent protective
effects of a higher social class. 
Several hypotheses have been put forward to explain the site-specific excesses of second primary
cancers in women with a primary breast cancer. A study based on the Piedmont Cancer Registry8
found an overall increased risk after 5 years since a diagnosis of first breast cancer, with a peak at 8
years, for cancers located in the oesophagus, stomach, lung or thyroid, suggestive of a late effect of
local radiotherapy of the breast tumour. However, the conclusions of a large study in the US SEER
population suggest that radiotherapy is responsible only for a small proportion of second primaries,
i.e. 8% (95% CI 7-9)20. In the same study, it was suggested that the proportion of second primary
cancers attributable to radiotherapy for breast cancer was even smaller, 5% (95% CI 4-6). Most
second primary cancers seemed to be attributable to other factors, such as lifestyle and genetics.
Tamoxifen has been suggested to explain the excess of endometrial cancer, and chemotherapy the
excess of leukemias (that we did not evaluate due to paucity of cases)17. A first pancreatic cancer
was associated with multiple second primary malignancies in one study28 although breast cancer
was not one of the common occurrences.
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Unlike  previous  investigations,  we  had  extensive  information  on  cancer  risk  factors,  including
reproductive  history,  anthropometric  measures,  dietary  and  other  lifestyle  information  such  as
physical  activity.  Some  of  these  variables  remained  statistically  significant  after  adjustment  for
multiple covariates: age at first cancer, smoking status, education, menopausal status, and history of
full term pregnancy. Being a never smoker, high educational level and post-menopausal status were
weakly  associated  with  a  reduction  of  risk  of  second  primary  cancers.  A  history  of  full-term
pregnancy is apparently associated with an inverse risk of second primary tumours, though there was
no trend with an increasing number of children (p for trend 0.169) and this association disappeared
after the exclusion of second breast, corpus uteri, and ovarian cancer. The potential mechanisms for
this association remain unclear. Our result is consistent with the finding from the WECARE study, in
which the number of full-term pregnancies was inversely associated with contralateral breast cancer
risk29.
The  analysis  by sites  showed expected  results,  due to  known specific  risk factors.  For  example
women who were current smokers had an increased risk of second lung cancer; a less trivial example
was the finding of a protective effect of dietary fiber for second breast cancer30. The main limitations
of our study are the lack of information on therapies, surgical treatments after recruitment (including
hysterectomy and mastectomy),  and the limited  information  on breast  cancer  subtypes  classified
according to hormone receptor status. In spite of this, the strong excess of risk in women with more
extended tumours (pT3 or more) who were probably treated with more aggressive therapies, may
suggest an effect of therapies in the development of a second cancer.  Moreover, the information
about risk factors for the subjects involved in the EPIC study is limited to recruitment; so we cannot
take into account the possible changes in risk factors, due for example to the diagnosis of the first
tumour. Another limitation is that the dates of diagnosis for the cases were from 1993 onwards and
therapies  changed  during  these  years  (for  example  current  radiotherapy  is  less  toxic  than
radiotherapy in the early ‘90s). Finally, our study is limited to invasive cancers, while women with in
situ tumours face a therapeutic approach similar to women with low-stage invasive breast cancer.
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In conclusion, we describe a higher risk (30% increase) of second primary cancers in a large cohort
of women with breast cancer.  Several risk factors were associated with an increase (Age at  first
tumour, smoking status, higher stage) or a decrease (higher education, menopausal status, history of
full-term  pregnancy)  of  second  primary  tumours.  These  findings  are  useful  for  health  services
planning, including screening and the development of specific guidelines for the follow-up of breast
cancer patients.
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Table 1 – Descriptive analysis of baseline characteristics of the cohort of 10,045 women with breast
cancer
Variable (missing values) Person  years
by category
Women  with  breast  cancer
only (n=10,553)
Women with second cancers 
(n=492) p-value
Means /Number SD/% Means/Number SD/% 
Age (years) (0/0) 59.81 8.48 59.96 (8.39) 8.39 0.70
BMI (0/0) 
Normal weight 32,914 6,232 59.05 264 53.66
0.05
Overweight - 16,735 3,086 29.24 159 32.32
Obese 6,846 1,235 11.70 69 14.02
Physical activity (925/59)
Inactive 11,855 2,193 22.78 96 22.17
0.43
Moderate inactive 19,414 3,582 37.20 159 36.72
Moderate active 12,281 2,327 24.17 118 27.25
Active 8,500 1,526 15.85 60 13.86
Smoking status (294/16)
Never smokers 30,023 5,698 55.54 231 48.53
0.002
Former smokers 14,059 2,591 25.26 126 26.47
Current smokers 10,972 1,970 19.20 119 25.00
Education (288/23)
Primary school or none 16,157 2,871 27.97 155 33.05
0.006
Secondary school 25,854 4,882 47.56 226 48.19
High school 12,771 2,512 24.47 88 18.76
Menopausal status (22/2)
Premenopausal 12,464 2,523 23.96 90 18.37
0.003
Postmenopausal 30,384 5,452 51.77 284 57.96
Perimenopausal 11,805 2,255 21.41 95 19.39
Bilateral ovariectomy 1,728 301 2.86 21 4.29
History of full term pregnancy (475/25)
Never 7,290 1,380 13.69 80 17.13
0.03Ever 46,593 8,698 86.31 387 82.87
History of breast feeding (993/65)
Never 7,169 1,297 15.86 54 15.56
0.13Ever 36,379 6,883 84.14 293 84.44
Nutrients (106/8)
Total Fat (g/day) 77.46 (28.61) 28.61 75.28 (29.63) 29.63 0.10
Total  saturated  fatty  acids
(g/day) 30.66 (12.92) 12.92 30.30 (13.37) 13.37 0.55
Total dietary fibre (g/day) 22.18 (7.63) 7.63 21.60 (8.01) 8.01 0.10
Energy (kcal) 1,973.57 (582.91) 582.91 1,936.66 (585.46) 585.46 0.17
Stage of first Breast Cancer tumour (4479/275)
Primary Tumour stage 1 (PT1) 21,941 4,375 72.03 125 57.60
<0.001
PT2 7,170 1,436 23.64 45 20.74
PT3 or more 1,295 263 4.33 47 21.66
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Table 2 – Age-adjusted (WORLD population) second tumour incidence rates by country and by
broad geographical region
Country Women(N) Person-years
Second
cancers (N) °
Rate (per 1,000
per year)
Second cancers
excl. breast (N)
Rate excl.
breast (per
1,000 per
year)
France 2865
             13,061
104
7.96
(6.43-9.49)
58
4.44
(3.30-5.58)
Italy 994
5,276
35
6.63
(4.44-8.83)
Spain 463
2,602
7
2.69
(0.70-4.68)
United Kingdom 1590
8,169
82
10.04
(7.86-12.21)
71
8.69
(6.67-10.71)
The Netherlands 851
4,927
69
14.00
(10.70-17.31)
34
6.90
(4.58-9.22)
Greece 181
915
1
1.09
(0-3.23)
Germany 794
3,352
20
5.97
(3.35-8.58)
19
5.67
(3.12-8.22)
Sweden 1131
7,006
65
9.28
(7.02-11.53)
53
7.56
(5.53-9.60)
Denmark 1315
7,423
61
8.22
(6.15-10.28)
47
6.33
(4.52-8.14)
Norway 861
3,765
48
12.75
(9.14-16.35)
27
7.17
(4.66-9.88)
Southern Europe* 1638
8,793
43
4.89
(3.43-6.35)
Center Europe¶ 4510
21,340
193
9.04
(7.77-10.32)
111
5.20
(4.23-6.17)
Northern Europe§ 4897
26,362
256
9.71
(8.52-10.90)
198
7.51
(4.46-8.56)
* Italy, Spain, Greece; ¶ France, The Netherlands, Germany; §The UK, Sweden, Denmark, Norway 
18
° These analyses were performed only on subjects from France, the UK, The Netherlands, Sweden,
Denmark  and  Norway  because  these  centres  provided  information  on  second  primary  breast
tumours. 
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Table 3 – Second primary tumours after breast cancer. Standardized Incidence Ratios (SIR) and
95% Confidence Intervals (95% CI) by type of tumour (WORLD population)
Type of tumour Observed
cancer
SIR 95% CI
Colorectum 65 1.71 1.43-2.04
Pancreas 13 0.70 0.32-1.31
Lung 33 1.31 0.98-1.72
Melanoma 27 2.12 1.63-2.70
Breast* 139 1.15 1.02-1.29
Endometrium 39 2.18 1.75-2.70
Ovary 25 1.28 0.91-1.74
Kidney 16 2.40 1.57-3.52
Thyroid gland 14 1.71 1.11-2.54
Lymphomas 29 1.80 1.31-2.40
All but breast cancers 352 1.30 1.18-1.42
All cancers* 492 1.18 1.06-1.31
* These analyses were performed only  on subjects from France, the UK, The Netherlands, Sweden,
Denmark  and  Norway  because  these  centres  provided  information  on  second  primary  breast
tumours. 
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Table 4 - Analysis of risk factors for breast cancer in relation to second primary tumours: Hazard
Ratios  (HR)  and 95% Confidence  Intervals  (95% CI).  Multivariate  model  is  built  with  all  the
variables in the univariate models.
Variable Univariate models
N=492/10678
Multivariate model
N=426/9599
 HR 95% CI
p  for
trend HR 95% CI
p for 
trend
Age at first tumour 1.03 1.02 1.04 <0.001 1.04 1.03 1.06 <0.001
BMI
Normal weight Ref
0.004
Ref
0.11Overweight 1.22 1.00 1.50 1.10 0.88 1.38
Obese 1.44 1.10 1.89 1.29 0.96 1.74
Smoking status
Never smokers Ref
0.04
Ref
0.05Former smokers 1.02 0.82 1.28 0.96 0.76 1.22
Current smokers 1.30 1.03 1.64 1.33 1.04 1.70
Education
Primary school or none
(< 8 years of school) Ref
<0.001
Ref
0.03Secondary school(8-12 years of school) 0.75 0.60 0.92 0.85 0.68 1.07
High school
(> 12 years of school) 0.63 0.48 0.82 0.72 0.53 0.98
Menopausal status*
Premenopausal Ref
NA
Ref
NAPostmenopausal 1.22 0.96 1.56 0.69 0.48 0.98
Perimenopausal* 1.00 0.74 1.34 0.79 0.57 1.11
Bilateral ovariectomy 1.75 1.08 2.83 0.99 0.56 1.73
History of full-term pregnancy
Never Ref
0.03
Ref 0.003
Ever 0.76 0.60 0.97 0.68 0.53 0.87
Nutrients
Total fat (g/die) 1.00 1.00 1.00 0.94 1.00 0.99 1.02 0.66
Total  saturated  fatty  acids
(g/die) 1.00 0.99 1.01 0.91 0.99 0.96 1.01 0.35
Total dietary fibre (g/die) 0.99 0.98 1.00 0.13 0.98 0.96 1.00 0.09
Energy (kcal) 1.00 1.00 1.00 0.85 1.00 1.00 1.00 0.19
* Women were considered perimenopausal if their age is in between 46 and 55 years, and the 
menopausal status is unknown. 
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Table  5 –  Tumour  stage as  risk factor  for second primary tumours  among women with breast
cancer: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) – Models adjusted for age at
first tumour, BMI, smoking status, education, menopausal status, history of full-term pregnancy,
and nutrients. 
All cancer (N=217/5796)
Primary Tumour Stage 1 (PT1)
(125/4156) Ref <0.001
PT2 (45/1389) 1.11 0.79 1.57
PT3 or more (47/251) 5.38 3.77 7.67
All cancer but breast (N=118/5796)
PT1 (53/4156) Ref <0.001
PT2 (23/1389) 1.36 0.83 2.23
PT3 or more (42/251) 10.99 7.12 16.96
Colorectum (N=29/5796)
PT1 (5/4156) Ref <0.001
PT2 (9/1389) 5.15 1.71 15.55
PT3 or more (15/251) 47.03 16.63 133.02
Lung (N=7/5796)
PT1 (1/4156) Ref 0.002
PT2 (2/1389) 4.37 0.39 48.63
PT3 or more (4/251) 27.81 2.93 263.73
Breast (N=98/4030)*
PT1 (72/2970) Ref 0.86
PT2 (21/904) 0.90 0.55 1.48
PT3 or more (5/156) 1.07 0.42 2.69
Corpus Uteri (N=20/5796)
PT1 (19/4156) Ref NA
PT2 (1/1389) 0.22 0.02 1.65
PT3 or more (0/251) NA NA NA
* These analyses were performed only  on subjects from France, the UK, The Netherlands, Sweden,
Denmark  and  Norway  because  these  centres  provided  information  on  second  primary  breast
tumours. 
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HR p	  for	  trend HR p	  for	  trend
Age	  at	  first	  tumour 1,07 1,03 1,10 <0.001 1,11 1,06 1,17 <0.001
Normal	  weight
Overweight 1,34 0,77 2,33 1,01 0,56 1,83
Obese 1,89 0,95 3,73 1,01 0,45 2,27
Never	  smokers
Former	  smokers 1,39 0,77 2,49 1,42 0,76 2,65
Current	  smokers 1,21 0,62 2,35 1,38 0,68 2,80
Primary	  school	  or	  none
Secondary	  school 0,55 0,31 0,96 0,67 0,37 1,22
High	  school 0,44 0,20 0,95 0,43 0,17 1,04
Premenopausal
Postmenopausal 1,39 0,72 2,70 0,330 0,28 0,10 0,77 0,01
Perimenopausal 0,87 0,37 2,04 0,75 0,45 0,18 1,16 0,09
Bilateral	  ovariectomy 1,94 0,54 6,99 0,31 0,47 0,11 2,07 0,32
No
Yes 0,57 0,31 1,06 0,52 0,27 1,00
Total	  Fat	  (g/die) 1,00 0,99 1,00 0,93 0,99 0,95 1,02 0,50
Total	  saturated	  fatty	  acids	  (g/die) 1,00 0,98 1,02 0,73 1,01 0,94 1,08 0,78
Total	  dietary	  fibre	  (g/die) 1,00 0,98 1,04 0,63 1,00 0,95 1,05 0,99
Energy	  (kcal) 1,00 1,00 1,00 0,48 1,00 1,00 1,00 0,25
HR p	  for	  trend HR p	  for	  trend
Age	  at	  first	  tumour 1,08 1,03 1,12 0,001 1,15 1,07 1,24 <0.001
0,05
95%	  CI 95%	  CI
Ref Ref
Full	  term	  pregnancy
Nutrients
Variable
Univariate	  models	  	  	  N=33/10678 Multivariate	  model	  N=26/9599
Ref
0,07
Ref
Supplementary Table 1 - Analysis of risk factors for breast cancer in relation to second COLON 
cancer: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
Supplementary Table 2 - Analysis of risk factors for breast cancer in relation to second LUNG 
cancer: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
Education
Ref
0,02
Ref
0,05
Menopausal	  status
Ref
0,06
Ref
0,97
Smoking	  status
Ref
0,45
Ref
0,29
BMI
Variable Univariate	  models	  	  	  N=65/10678 Multivariate	  model	  N=57/9599
95%	  CI 95%	  CI
Normal	  weight
Overweight 0,78 0,34 1,80 1,12 0,46 2,73
Obese 1,57 0,62 3,96 1,36 0,43 4,30
Never	  smokers
Former	  smokers 2,38 0,75 7,53 2,06 0,54 7,86
Current	  smokers 10,62 3,87 29,12 9,93 3,11 31,72
Primary	  school	  or	  none
Secondary	  school 1,15 0,49 2,69 2,31 0,87 6,11
High	  school 0,49 0,13 1,88 1,22 0,28 5,26
Premenopausal
Postmenopausal 3,59 0,82 15,50 0,09 0,44 0,07 2,68 0,37
Perimenopausal 2,13 0,41 11,14 0,37 0,72 0,12 4,19 0,72
Bilateral	  ovariectomy 9,97 1,62 61,54 0,01 1,92 0,24 15,23 0,53
No
Yes 0,90 0,34 2,35 0,74 0,27 2,03
Total	  Fat	  (g/die) 1,00 0,99 1,01 0,97 1,03 0,98 1,08 0,29
Total	  saturated	  fatty	  acids	  (g/die) 1,00 0,97 1,03 0,95 0,92 0,83 1,02 0,10
Total	  dietary	  fibre	  (g/die) 0,95 0,90 1,00 0,06 0,93 0,86 1,00 0,08
Energy	  (kcal) 1,00 1,00 1,00 0,89 1,00 1,00 1,00 0,31
HR p	  for	  trend HR p	  for	  trend
Age	  at	  first	  tumour 0,98 0,96 1,01 0,22 1,02 0,98 1,06 0,28
Normal	  weight
Overweight 1,10 0,75 1,62 1,17 0,76 1,78
Obese 1,39 0,81 2,37 1,65 0,95 2,87
Never	  smokers
0,24
Ref
0,09
Ref
0,10
Ref
Smoking	  status
Supplementary Table 3 - Analysis of risk factors for breast cancer in relation to second BREAST 
cancer: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
Variable Univariate	  models	  	  	  N=139/8331
Multivariate	  model	  
N=121/7289
95%	  CI 95%	  CI
BMI
Ref
0,24
Menopausal	  status
Ref Ref
Full	  term	  pregnancy
Ref
0,83
Ref
0,56
Smoking	  status
Ref
<0.001
Ref
<0.001
Nutrients
Ref
0,40
Ref
0,53
Education
BMI
Ref
0,54
Ref
0,73
Former	  smokers 1,27 0,85 1,91 1,20 0,78 1,86
Current	  smokers 1,44 0,92 2,25 1,32 0,82 2,14
Primary	  school	  or	  none
Secondary	  school 0,90 0,59 1,36 0,89 0,57 1,40
High	  school 0,84 0,51 1,40 0,83 0,47 1,47
Premenopausal
Postmenopausal 0,60 0,39 0,91 0,02 0,61 0,32 1,17 0,14
Perimenopausal 0,82 0,52 1,28 0,38 0,94 0,55 1,61 0,83
Bilateral	  ovariectomy 0,41 0,10 1,69 0,22 0,39 0,08 1,79 0,22
No
Yes 0,64 0,41 0,99 0,58 0,37 0,90
Total	  Fat	  (g/die) 1,00 0,99 1,01 0,76 1,00 0,98 1,02 0,92
Total	  saturated	  fatty	  acids	  (g/die) 1,00 0,99 1,01 0,66 0,98 0,94 1,03 0,49
Total	  dietary	  fibre	  (g/die) 0,97 0,95 0,99 0,02 0,95 0,91 0,99 0,007
Energy	  (kcal) 1,00 1,00 1,00 0,94 1,00 1,00 1,00 0,09
HR p	  for	  trend HR p	  for	  trend
Age	  at	  first	  tumour 1,06 1,01 1,10 0,009 1,06 1,01 1,12 0,02
Normal	  weight
Overweight 1,59 0,78 3,24 1,59 0,72 3,51
Obese 1,66 0,59 4,64 1,26 0,37 4,13
Never	  smokers
Former	  smokers 0,70 0,29 1,65 0,49 0,18 1,31
Current	  smokers 0,68 0,24 1,89 0,57 0,18 1,80
Primary	  school	  or	  none
Secondary	  school 0,54 0,24 1,20 0,52 0,22 1,24
Ref
0,36
Ref
0,20
Education
Ref
0,39
Ref
0,46
BMI
Ref
0,06
Ref
0,44
Smoking	  status
0,02
Nutrients
Supplementary Table 4 - Analysis of risk factors for breast cancer in relation to second CORPUS 
UTERI cancer: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
Variable Univariate	  models	  	  	  N=39/10663 Multivariate	  model	  N=32/9587
0,24
95%	  CI 95%	  CI
Menopausal	  status
Ref Ref
Full	  term	  pregnancy
Ref
0,04
Ref
Education
Ref
0,50
Ref
0,57
0,10
High	  school 0,68 0,28 1,64 0,74 0,28 2,01
Premenopausal
Postmenopausal 2,59 1,00 6,83 0,05 1,25 0,31 5,07 0,75
Perimenopausal 1,20 0,36 3,40 0,77 0,99 0,25 3,91 0,99
Bilateral	  ovariectomy NA NA NA NA NA NA NA NA
No
Yes 0,72 0,29 1,73 0,69 0,26 1,84
Total	  Fat	  (g/die) 1,01 1,00 1,01 0,16 1,02 0,98 1,06 0,26
Total	  saturated	  fatty	  acids	  (g/die) 1,01 0,99 1,03 0,30 0,96 0,89 1,03 0,27
Total	  dietary	  fibre	  (g/die) 1,03 0,99 1,07 0,11 1,00 0,94 1,07 0,93
Energy	  (kcal) 1,00 1,00 1,00 0,14 1,00 1,00 1,00 0,84
HR p	  for	  trend HR p	  for	  trend
Age	  at	  first	  tumour 1,05 1,03 1,06 <0.001 1,05 1,03 1,07 <0.001
Normal	  weight
Overweight 1,27 1,01 1,62 1,09 0,84 1,41
Obese 1,48 1,08 2,02 1,19 0,84 1,68
Never	  smokers
Former	  smokers 0,94 0,72 1,23 0,87 0,65 1,16
Current	  smokers 1,27 0,97 1,66 1,35 1,01 1,80
Primary	  school	  or	  none
Secondary	  school 0,69 0,54 0,89 0,85 0,65 1,11
High	  school 0,56 0,40 0,77 0,69 0,49 0,99
Premenopausal
Postmenopausal 1,72 1,26 2,35 0,01 0,77 0,50 1,18 0,24
Perimenopausal 1,13 0,77 1,66 0,53 0,74 0,48 1,13 0,17
Bilateral	  ovariectomy 2,77 1,62 4,71 <0.001 1,29 0,69 2,42 0,43
No
Menopausal	  status
Ref Ref
Full	  term	  pregnancy
Nutrients
Ref
0,46
Ref
0,46
0,39 0,46
Supplementary Table 5 - Analysis of risk factors for breast cancer in relation to ALL second 
cancer BUT BREAST: Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) 
Variable Univariate	  models	  	  	  N=352/10678
Multivariate	  model	  
N=304/9599
95%	  CI 95%	  CI
BMI
Ref
0,006
Ref
0,39
Smoking	  status
Ref
0,15
Ref
0,11
Education
Ref
<0.001
Ref
0,03
Menopausal	  status
Ref Ref
Full	  term	  pregnancy
Ref
0,17
Ref
0,04
Yes 0,81 0,61 1,09 0,73 0,54 0,99
Total	  Fat	  (g/die) 1,00 1,00 1,00 0,74 1,00 0,99 1,02 0,71
Total	  saturated	  fatty	  acids	  (g/die) 1,00 0,99 1,01 0,86 0,99 0,96 1,02 0,55
Total	  dietary	  fibre	  (g/die) 1,00 0,98 1,01 0,67 1,00 0,97 1,02 0,78
Energy	  (kcal) 1,00 1,00 1,00 0,81 1,00 1,00 1,00 0,63
Nutrients
0,17 0,04
